Abstract
Increasing experimental evidence points to direct effects of glucagon-like peptide-1 (GLP-1) and its analogs on the heart and circulatory system, in addition to the well-established, antidiabetic actions of these agents on glucose and on the energy metabolism. These effects are primarily vasodilation, diminished heart muscle loss after myocardial infarction and a contractility increase of a weak left ventricle. A few, small patient trials appear to support the latter effect. Experimental results suggest the myocardium-saving effect following coronary occlusion and reperfusion as particularly suitable for clinical testing.
MeSH terms
-
Cardiomyopathy, Dilated / drug therapy
-
Cardiovascular System / drug effects*
-
Cardiovascular System / metabolism
-
Energy Metabolism / drug effects
-
Exenatide
-
Glucagon-Like Peptide 1 / analogs & derivatives
-
Glucagon-Like Peptide 1 / pharmacology
-
Glucagon-Like Peptide 1 / physiology*
-
Glucagon-Like Peptide 1 / therapeutic use
-
Glucagon-Like Peptide-1 Receptor
-
Heart / drug effects
-
Humans
-
Hypoglycemic Agents / pharmacology*
-
Hypoglycemic Agents / therapeutic use
-
Liraglutide
-
Myocardial Reperfusion Injury / drug therapy
-
Myocardium / metabolism
-
Peptides / pharmacology
-
Peptides / therapeutic use
-
Receptors, Glucagon / drug effects
-
Receptors, Glucagon / metabolism
-
Venoms / pharmacology
-
Venoms / therapeutic use
Substances
-
GLP1R protein, human
-
Glucagon-Like Peptide-1 Receptor
-
Hypoglycemic Agents
-
Peptides
-
Receptors, Glucagon
-
Venoms
-
Liraglutide
-
Glucagon-Like Peptide 1
-
Exenatide